Abstract

Intrinsic expression of the multidrug resistance (MDR) transporter P-glycoprotein (Pgp) may be regulated by reactive oxygen species (ROS). A transient expression of Pgp was observed during the growth of multicellular tumor spheroids. Maximum Pgp expression occurred in tumor spheroids with a high percentage of quiescent, Ki-67-negative cells, elevated glutathione levels, increased expression of the cyclin-dependent kinase inhibitors p27Kip1 and p21WAF-1 as well as reduced ROS levels and minor activity of the mitogen-activated kinase (MAPK) members c-Jun amino-terminal kinase (JNK), extracellular signal-regulated kinase ERK1,2, and p38 MAPK. Raising intracellular ROS by depletion of glutathione with buthionine sulfoximine (BSO) or glutamine starvation resulted in down-regulation of Pgp and p27Kip1, whereas ERK1,2 and JNK were activated. Down-regulation of Pgp was furthermore observed with low concentrations of hydrogen peroxide and epidermal growth factor, indicating that ROS may regulate Pgp expression. The down-regulation of Pgp following BSO treatment was abolished by agents interfering with receptor tyrosine kinase signaling pathways, i.e. the protein kinase C inhibitors bisindolylmaleimide I (BIM-1) and Ro-31-8220, the p21ras farnesyl protein transferase inhibitor III, the c-Raf inhibitor ZM 336372 and PD98059, which inhibits ERK1,2 activation. ROS involved as second messengers in receptor tyrosine kinase signaling pathways may act as negative regulators of Pgp expression.

Highlights

  • The treatment of cancer is limited by either intrinsic or acquired expression of multidrug resistance transporters, including Pgp.1 The Pgp-mediated MDR phenotype is generally characterized by a decreased cellular drug accumulation owing to an enhanced drug efflux and is caused by the overexpression of the drug transporter [1,2,3]

  • Transient Expression of Pgp in Multicellular Tumor Spheroids—We have previously reported on the development of an intrinsic Pgp-mediated MDR in multicellular prostate tumor spheroids of the DU-145 cell line, which paralleled the induction of cell quiescence in the depth of the multicellular tissue [7, 8]

  • The present study reports on the correlation of endogenous intracellular reactive oxygen species (ROS) levels and the intrinsic expression of Pgp in multicellular prostate tumor spheroids of different size classes

Read more

Summary

The abbreviations used are

P-glycoprotein; MDR, multidrug resistance; ROS, reactive oxygen species; MAPK, mitogen-activated protein kinase; BSO, buthionine sulfoximine; EGF, epidermal growth factor; FPT inhibitor III, farnesyl protein transferase inhibitor III; ZM 336372, N-[5-(3-dimethylaminobenzamido)-2-methylphenyl]-4hydroxybenzamide; BIM-1, bisindolylmaleimide I; Ro-31-8220, bisindolylmaleimide IX; PD98059, 2Јamino-3Ј-methoxyflavone; DCF, 2Ј,7Ј-dichlorofluorescein; H2DCFDA, 2Ј,7Ј-dichlorodihydrofluorescein diacetate; PBS, phosphate-buffered saline; PBST, PBS supplemented with 1% Triton X-100; H2DCF, 2Ј,7Ј-dichlorodihydrofluorescein; RT-. There is increasing evidence that Pgp-mediated MDR is likewise developing in the multicellular context of tumor tissues, without previous treatment with anti-cancer agents (4 – 8). This intrinsic Pgp-mediated MDR may represent a so far underestimated common in vivo situation, which may even worsen the efficacy of chemotherapeutic regimen. It has been pointed out that the expression of Pgp may be redox-regulated, because down-regulation of Pgp and reversal of the MDR phenotype was achieved by treatment of tumor cells with tumor necrosis factor ␣ [12], which is known to utilize low levels of ROS in its signal transduction pathway [13]. The modulation of the intracellular redox state by BSO or other ROS-generating agents is apparently suitable in vitro to circumvent the MDR phenotype and may be useful in vivo to promote the efficacy of chemotherapeutic regimen in anti-cancer treatment

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call